Skip to main content
Candy Bright-Russell

Featured Patient Story

Candy Bright-Russell

Three years ago a dream came true. After years of trying, l was blessed to give birth to my son.

read more

Latest News Story Headlines

Alnylam Announces U.S. Food and Drug Administration Acceptance of Supplemental New Drug Application for Vutrisiran for the Treatment of ATTR Amyloidosis with Cardiomyopathy

Nov 25, 2024

− Prescription Drug User Fee Act (PDUFA) Date Set for March 23, 2025 −

read full article
Attruby™ (acoramidis), a Near Complete TTR Stabilizer (≥90%), approved by FDA to Reduce Cardiovascular Death and Cardiovascular-related Hospitalization in ATTR-CM Patients

11.22.2024 at 7:12 PM EST

read full article
Intellia Announces First Clinical Evidence from Ongoing Phase 1 Study that Nexiguran Ziclumeran (nex-z), an In Vivo CRISPR/Cas9-Based Gene Editing Therapy, May Favorably Impact Disease Progression in Transthyretin (ATTR) Amyloidosis

CAMBRIDGE, Mass., Nov. 16, 2024 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc.

read full article

Calendar & Upcoming Events

Office Closed

Our office will be closed on December 24th and 25th for the Holiday.

view all event details

Office Closed

view all event details

Webinar: Kicking off your new year right!

 Webinar Session, Wednesday, Jan. 1st, 2025 at 6 PM (ET)

view all event details

Amyloidosis Videos

Our Latest Webinar

Updates in AL amyloidosis: Fast Forward in 2024!

Heather Landau, MD - Memorial Sloan Kettering Cancer Center - New York, NY

Sign Up for the Latest Updates

Get news from Amyloidosis Foundation
in your inbox

By submitting this form, you are consenting to receive marketing emails from : Amyloidosis Foundation, 7151 N. Main St., Suite 2, Clarkston, MI, 48346, US, https://www.amyloidosis.org. You can revoke your consent to receive emails at any time by using SafeUnsubscribe© link, found at the bottom of every email. Emails are serviced by Constant Contract.